Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. & Maxim Group...
17 Março 2014 - 9:30AM
Marketwired
Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With
the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
TORONTO, ON--(Marketwired - Mar 17, 2014) - Medifocus, Inc.
(OTCQX: MDFZF) (TSX-VENTURE: MFS) (Medifocus or the Company), a
leader in the development and commercialization of focused
microwave energy to treat cancer and other diseases, is pleased to
announce that Medifocus Asia, Ltd. has entered into an advisory
agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to
help identify distribution and joint venture partners for the
Company's cutting-edge Prolieve® Thermodilatation System in Japan
and South Korea.
Under the terms of the agreement, Euro Japan Marketing and Maxim
Group will serve as co-advisors to Medifocus Asia, Ltd. as it works
to expand its presence throughout Japan and South Korea. They
will help identify distribution and joint partners which can
further the Company's position as an emerging leader within the
Benign Prostatic Hyperplasia ("BPH") treatment market. Benign
Prostatic Hyperplasia is the medical term for enlarged prostate, a
non-cancerous urological disease in which the prostate enlarges and
constricts the urethra. BPH is an age-related
disorder. It is generally estimated that approximately 50% of
all men over the age of 55 and 90% of all men over 75 will have BPH
symptoms at various times.
The Company has already made significant progress in its effort
to build its presence in the Asia-Pacific market through its joint
venture partnership with Ideal Concept Group, Ltd. (ICG), a Hong
Kong-based company with extensive expertise in business development
in Greater China and other Asia-Pacific countries. ICG and
Medifocus own 60% and 40% of Medifocus Asia, respectively.
Dr. Augustine Y. Cheung, President and CEO of Medifocus,
commented, "Since the formation of Medifocus Asia in November 2013,
we have worked diligently with Ideal Concept Group to introduce our
unique thermotherapy technology platforms to the Asia-Pacific
marketplace. Through their deep connections and resources, we
have taken important steps to position our Prolieve® system at the
forefront of one of world's largest BPH patient populations. With a
population of 4.3 billion and growing economies, the Asia market
presents enormous potentials for our products. We believe the
Prolieve® therapy offers a more patient-friendly alternative to
medication and other more invasive surgical-based treatments
without the complications and side effects associated with those
procedures."
"We are pleased to expand our global team with the engagement of
Euro Japan Marketing and Maxim Group as they offer the ability to
further our success within the Asia-Pacific region by assisting our
expansion in Japan and South Korea. Similar to China, these
countries offer a vast opportunity for our business as they
represent a male population of over 85 million."
Christopher Jackson, Managing Director of Euro Japan, commented,
"With aging populations and a high incidence of Medifocus' target
indications, including prostate cancer and urological diseases,
both Japan and South Korea are well-placed to become key regions
for Medifocus' future business. The minimally invasive microwave
heat system that does not cause harm to surrounding tissue is a
very neat technology that offers key benefits in terms of treatment
regime and quality of life. We look forward to working with
Medifocus to secure strong local partners in both
territories."
About Medifocus, Inc.
Medifocus owns two fully developed technology platforms with
comprehensive US and international patent protection: (1) The
Endo-thermotherapy Platform -- a catheter-basis focused heat
technology platform that utilizes natural body openings to deliver
precise microwave thermotherapy to the diseased sites. The U.S. FDA
approved Prolieve Thermodilatation System for the treatment of
Benign Prostatic Hyperplasia ("BPH") was developed based on
Endo-thermotherapy and is currently generating revenue, and (2) The
Adaptive Phased Array (APA) Microwave Focusing Platform -- invented
by MIT, licensed to Medifocus, directs precisely focused microwave
energy at tumor center to induce shrinkage or eradication of tumors
without undue harm to surrounding tissue. The Company's APA 1000
Breast Cancer Treatment System, developed from the APA technology
platform, has received approval from the U.S. FDA and Health Canada
to conduct the pivotal Phase III clinical trials. The Company
believes that these two technology platforms can provide the design
basis for the development of multiple cancer treatment systems for
surface, subsurface and deep seated localized and regional cancers.
Please visit www.medifocusinc.com, www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
for more details.
About Euro-Japan Marketing Ltd
Euro Japan is a long-established consultancy company that,
through offices in London and Tokyo, provides consultancy services
and advice to biotech and medtech companies in both regions. This
includes identifying and securing licensing partners and
distributors; securing funding; and developing positive
relationships with key stakeholders. Euro Japan has extensive
knowledge of the biopharma and medtech sectors in both Japan and
South Korea (until recently, it had a sister company, Euro Korea
Marketing Limited, with an office in Seoul) and is able to leverage
its network to the benefit of clients. More details about Euro
Japan can be found at www.eujapan.co.jp
About Maxim Group LLC:
Maxim Group LLC is a full-service investment banking firm
headquartered in New York. Maxim Group provides a full array
of financial services including investment banking; private wealth
management; and global institutional equity, fixed-income and
derivatives sales and trading as well as equity research. The
investment banking group focuses on middle market and emerging
growth companies within the shipping, energy, healthcare,
technology, retail, and business and financial services
sectors. The institutional coverage of Maxim Group spans North
and South America, Europe and Asia. Maxim Group LLC is
registered as a broker-dealer with the U.S. Securities and Exchange
Commission and is a member of the following: Financial Industry
Regulatory Authority (FINRA); Municipal Securities Rulemaking Board
(MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ
Stock Market and the NYSEARCA, Inc. To learn more about Maxim
Group, visit www.maximgrp.com.
Forward-Looking Statements
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of CCTI, Inc., and members of their management
as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve
risks and uncertainties, and that actual results may differ
materially from those contemplated by such forward-looking
statements. Important factors currently known to management that
could cause actual results to differ materially from those in
forward-statements include fluctuation of operating results, the
ability to compete successfully and the ability to complete
before-mentioned transactions. The company undertakes no obligation
to update or revise forward-looking statements to reflect changed
assumptions, the statements to reflect changed assumptions, the
occurrence of unanticipated events or changes to future operating
results.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Company Contact: John Mon COO Medifocus, Inc. Tel: 410-290-5734
JohnMon@medifocusinc.com Investor Relations Contact: Robert
Giordano Consulting for Strategic Growth 1 T: 917-327-3938
rgiordanonyc@gmail.com
Medifocus (CE) (USOTC:MDFZF)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Medifocus (CE) (USOTC:MDFZF)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024